Nat Med·· 17 hours agoPickScore88
Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.
In brief
A 5-year analysis of the phase 3 RELATIVITY-047 trial (NCT03470922) shows that relatlimab plus nivolumab improved progression-free survival, overall survival, and melanoma-specific survival versus nivolumab monotherapy in advanced melanoma.
Why it matters
Same trial with nivolumab monotherapy control reports 5-year PFS, OS, MSS and LAG-3 stratification, enabling comparison of long-term benefit and primary resistance.
Source: Nat Med · doi.org